

Annual Funding for NIH and FDA

JDRF is the leading global organization funding T1D research, with a mission to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. One of the important ways JDRF advances its mission is to ensure the federal government is investing in T1D research. JDRF's top legislative priority is renewal of [the Special Diabetes Program \(SDP\)](#), which contributes \$150 million annually to T1D research through the National Institutes of Health (NIH) and will expire if it is not renewed by September 30. JDRF also continually monitors and advocates for strong annual federal funding for the NIH¹ as with the U.S. Food and Drug Administration (FDA)².

Current Funding Status

The NIH and FDA are funded currently at \$32.3 billion and \$4.745 billion respectively. These are the funding levels set by Congress and signed by the President in Fiscal Year 2016 (FY16). Since Congress was unable to complete the appropriations process by the start of FY17 on October 1, 2016, they enacted a Continuing Resolution (CR) which extended the FY16 values until December 9, 2016 and then again until April 28, 2017 to give President Trump time to organize his fiscal priorities.

In March, the Administration released its FY18 discretionary budget proposal which included a \$5.8 billion cut for NIH. The proposal also calls for over \$2 billion in fees from industry for FDA to review their products. Congress must now decide what to do with this budget proposal while also completing the FY17 appropriations process.

JDRF participates as part of several broad coalitions to support the highest funding levels possible for the NIH and the FDA. In particular, JDRF serves as a member of the Ad Hoc Group for Medical Research, a coalition of over 200 patient and health advocacy organizations and research institutions. JDRF is also part of the Alliance for a Stronger FDA, which unites a broad spectrum of patient groups, consumer advocates, biomedical research advocates, health professionals and industry to increase appropriations for the FDA. Participation in these groups comes in addition to JDRF's direct work to advance T1D research, treatments and therapies at these agencies.

Recently, JDRF [joined with the Ad Hoc Group](#) in urging Congress to reject the Administration's proposed cuts to NIH and to finalize the FY17 appropriations process with \$34.1 billion for NIH, as approved by the Senate Appropriations Committee in June 2016. We also urge Congress to continue this budget

¹ The [National Institutes of Health \(NIH\)](#) is the government agency that administers federal funding for medical research across the country and around the world. Within the NIH, the National Institute of Diabetes and Digestive and Kidney Diseases ([NIDDK](#)) is the lead institute for coordinating and conducting research to cure, treat and prevent T1D and its complications. In addition to administering the Special Diabetes Program (SDP) funds, NIDDK (and other institutes within NIH) awards grants on a competitive basis with funding the NIH receives from Congress annually through the annual appropriations process.

² The U.S. [Food and Drug Administration \(FDA\)](#) is tasked with assuring the safety, efficacy and security of drugs, biologics and medical devices, including artificial pancreas technology and other new diabetes therapies. JDRF and the T1D community have a vested interest in the actions of the FDA and its funding levels as new treatments will require FDA review and approval before becoming available.

trajectory with a \$2 billion increase over FY17 for NIH in FY18, in addition to funds included in the 21st Century Cures Act for targeted initiatives.

JDRF will continue to monitor and engage on the FY18 budget, as well as on the completion of the FY17 appropriations process and then the late emerging FY18 appropriations proposals. The process will also get further complicated by initial work on the budget for FY19.

